Evaluation of 30-day mortality in patients undergoing gastrointestinal endoscopy in a tertiary hospital: a 3-year retrospective survey.

Autor:	Chatelanat O; Department of Gastroenterology and Hepatology, Geneva University Hospitals, Geneva, Switzerland olivier.chatelanat@hcuge.ch., Spahr L; Department of Gastroenterology and Hepatology, Geneva University Hospitals, Geneva, Switzerland., Bichard P; Department of Gastroenterology and Hepatology, Geneva University Hospitals, Geneva, Switzerland., Bochatay L; Department of Gastroenterology and Hepatology, Groupement Hospitalier de l'Ouest Lémanique, Nyon, Switzerland., Goossens N; Department of Gastroenterology and Hepatology, Geneva University Hospitals, Geneva, Switzerland., Bastid C; Department of Gastroenterology and Hepatology, Geneva University Hospitals, Geneva, Switzerland., Frossard JL; Department of Gastroenterology and Hepatology, Geneva University Hospitals, Geneva, Switzerland.
Jazyk:	angličtina
Zdroj:	BMJ open gastroenterology [BMJ Open Gastroenterol] 2022 Nov; Vol. 9 (1).
DOI:	10.1136/bmjgast-2022-000977
Abstrakt:	Objective: Despite international guidelines recommendations to use mortality as a quality criterion for gastrointestinal (GI) procedures, recent studies reporting these data are lacking. Our objective was to report death causes and rate following GI endoscopies in a tertiary university hospital. Design: We retrospectively reviewed all GI procedures made between January 2017 and December 2019 in our tertiary hospital in Switzerland. Data from patients who died within 30 days of the procedure were recorded. Results: Of 18 233 procedures, 251 patients died within 30 days following 345 (1.89%) procedures (244/9180 gastroscopies, 53/5826 colonoscopies, 23/2119 endoscopic ultrasound, 19/911 endoscopic retrograde cholangiopancreatography, 6/197 percutaneous endoscopic gastrostomies). Median age was 70 years (IQR 61-79) and 173/251 (68.92%) were male. Median Charlson Comorbidity Index was 5 (IQR 3-7), and 305/345 procedures (88.4%) were undertaken on patients with an ASA score ≥3. Most frequent indications were suspected GI bleeding (162/345; 46.96%) and suspected cancer or tumourous staging (50/345; 14.49%). Major causes of death were oncological progression (72/251; 28.68%), cardiopulmonary failure or cardiac arrest of unkown origin (62/251; 24,7%) and liver failure (20/251; 7.96%). No deaths were caused by complications such as perforation or bleeding. Conclusions: Progression of malignancies unrelated to the procedure was the leading cause of short-term death following a GI procedure. After improvements in periprocedural care in the last decades, we should focus on patient selection in this era of new oncological and intensive care therapies. Death rate as a quality criterion is subject to caution as it depends on indication, setting and risk benefit ratio. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu